Corcept’s Lifyorli: A New Dawn in Platinum-Resistant Ovarian Cancer Treatment
Redwood City, California – March 26, 2026 – Corcept Therapeutics has received FDA approval for Lifyorli (relacorilant) in combination with nab-paclitaxel, marking a significant advancement in the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. This approval, the first for a selective glucocorticoid receptor antagonist (SGRA), offers a new hope for patients who have already undergone one to three prior systemic treatment regimens, including bevacizumab.
Understanding Platinum-Resistant Ovarian Cancer
Ovarian cancer is the fifth leading cause of cancer death among women. The challenge arises when the cancer becomes resistant to platinum-based chemotherapy, a common first-line treatment. Approximately 20,000 women in the U.S. And a similar number in Europe annually face this resistance and require new therapeutic options.
How Lifyorli Works: Targeting the Cortisol Connection
Lifyorli represents a novel approach to cancer treatment by targeting the glucocorticoid receptor. Cortisol, often known as the “stress hormone,” can contribute to tumor growth and resistance to chemotherapy. Lifyorli works by blocking the effects of cortisol, potentially increasing the effectiveness of chemotherapy drugs like nab-paclitaxel. Unlike other treatments, Lifyorli does not require biomarker testing for patient selection.
ROSELLA Trial: Demonstrating Significant Clinical Benefit
The FDA approval is based on the positive results from the ROSELLA clinical trial, involving 381 patients. The trial demonstrated a 35% reduction in the risk of death for patients treated with Lifyorli plus nab-paclitaxel compared to those receiving nab-paclitaxel alone (hazard ratio 0.65, p-value 0.0004). Median overall survival increased from 11.9 months to 16.0 months – a difference of 4.1 months. Progression-free survival also showed improvement, with a 30% reduction in the risk of disease progression (hazard ratio 0.70, p-value 0.0076).
Safety Profile and Considerations
The combination of Lifyorli and nab-paclitaxel was generally well-tolerated. Common adverse reactions included decreased hemoglobin, decreased neutrophils, fatigue, nausea, and diarrhea. The prescribing information includes warnings and precautions related to neutropenia, severe infections, adrenal insufficiency, exacerbation of conditions treated with glucocorticoids, and embryo-fetal toxicity. Contraindications include patients requiring corticosteroids for life-saving indications.
The Broader Implications: A Shift in Oncology
Corcept’s success with Lifyorli signifies a potential shift in oncology, highlighting the importance of modulating the glucocorticoid receptor. Founded in 1998, Corcept has long focused on the role of cortisol in various diseases. This approval marks a transition from a niche endocrinology player to a diversified oncology contender. The company is currently exploring relacorilant’s potential in other cancers, including endometrial, cervical, pancreatic, and prostate cancer.
Future Directions: Expanding the Role of SGRAs
The approval of Lifyorli opens doors for further research into the potential of selective glucocorticoid receptor antagonists in oncology. Researchers are investigating whether modulating cortisol levels can enhance the effectiveness of other cancer treatments and improve patient outcomes across a wider range of malignancies. The focus on the glucocorticoid receptor represents a novel avenue for drug development, potentially offering new hope for patients with difficult-to-treat cancers.
Frequently Asked Questions
What is Lifyorli?
Lifyorli (relacorilant) is the first FDA-approved selective glucocorticoid receptor antagonist, used in combination with nab-paclitaxel to treat platinum-resistant ovarian cancer.
How does Lifyorli work?
Lifyorli blocks the effects of cortisol, a hormone that can contribute to tumor growth and resistance to chemotherapy.
Who is eligible for Lifyorli treatment?
Adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatments, including bevacizumab, are eligible.
What were the key findings of the ROSELLA trial?
The ROSELLA trial showed a significant improvement in overall survival and progression-free survival for patients treated with Lifyorli plus nab-paclitaxel.
What are the potential side effects of Lifyorli?
Common side effects include decreased hemoglobin, decreased neutrophils, fatigue, nausea, and diarrhea. Serious side effects are possible and should be discussed with a healthcare professional.
Pro Tip: Always discuss any new medication with your doctor to understand the potential benefits and risks, and to ensure it’s the right treatment option for your individual needs.
Did you know? Corcept Therapeutics has been focused on modulating cortisol for over 25 years, demonstrating a long-term commitment to this innovative approach to treating serious diseases.
Learn more about Lifyorli and connect with support resources at www.corcept.com.
